

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 6, 2024

Rabbit Anti-Human DR5 Polyclonal Antibody, Unconjugated

RRID:AB_10692107

Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 3696, RRID:AB_10692107)

Antibody Information

URL: http://antibodyregistry.org/AB_10692107

Proper Citation: (Cell Signaling Technology Cat# 3696, RRID:AB_10692107)

Target Antigen: Human DR5

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W. Consolidation on 10/2018: AB_10692107, AB_2204939.

Antibody Name: Rabbit Anti-Human DR5 Polyclonal Antibody, Unconjugated

Description: This polyclonal targets Human DR5

Target Organism: human

Antibody ID: AB_10692107

Vendor: Cell Signaling Technology

Catalog Number: 3696

Ratings and Alerts

No rating or validation information has been found for Rabbit Anti-Human DR5 Polyclonal Antibody, Unconjugated.

No alerts have been found for Rabbit Anti-Human DR5 Polyclonal Antibody, Unconjugated.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Shivange G, et al. (2021) A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors. Cell reports, 37(5), 109953.

Einstein JM, et al. (2021) Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer. Molecular cell, 81(15), 3048.

Tufano M, et al. (2021) FKBP51 Affects TNF-Related Apoptosis Inducing Ligand Response in Melanoma. Frontiers in cell and developmental biology, 9, 718947.

Hernandez Borrero L, et al. (2021) A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53. eLife, 10.

Shivange G, et al. (2018) A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer. Cancer cell, 34(2), 331.

Hartwig T, et al. (2017) The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2. Molecular cell, 65(4), 730.